Skip to main content
SanofiPartnership ended

Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272

Source: Autobound Signal API · 89 signals tracked for Sanofi · updated

Get Sanofi's live signals in Claude or ChatGPT, or by API

AskWhat changed at Sanofi this week? Use Autobound signals for sanofi.com.

What happened

Sanofi notified Nurix Therapeutics of its decision to terminate their SAR448272 oral STAT6 degrader development program.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

BRISBANE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today announced that Sanofi notified Nurix of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and to terminate the SAR448272 program. As a result of Sanofi's decision, Nurix does not anticipate receiving any of the future development, regulatory and commercial milestone payments or royalties for which it has been eligible under the collaboration with respect to the SAR448272 program. Nurix remains eligible to receive milestone payments and royalties with respect to its other previously announced licensed programs developed under the collaboration agreement that Sanofi may at its discretion develop further into clinical candidates. Today's announcement does not change Nurix's recently issued cash runway guidance, with cash, cash equivalents and marketable securities of $1.1 billion as of August 31, 2026, sufficient to fund operations into the second half of 2029. "While today's news is disappointing, Nurix remains in a strong position, with a substantial cash runway, three clinical-stage programs across our wholly owned and partnered portfolio, and an exciting preclinical pipeline," said Arthur T. Sands, M.D., Ph.D., president and...

Keep reading with a free account

The rest of this article, and every signal for Sanofi, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Partnership ended

What this signalsAn ended partnership often leaves a gap another vendor can fill.

Takes effect
Nov 3, 2026
Location
Brisbane, California, United States

Companies

  • Nurix Therapeutics, Inc.Partnernurixtx.com

More partnership ended signals at other companies

The full record

From the Signal API record

Extraction

Confidence
95%
Detected
Nov 3, 2026
signal_type
news
signal_subtype
ends_partnership_with

Use this data

Get every partnership ended signal for Sanofi and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Sanofi this week?”

  2. Send it to your own tools

    The Signal API returns partnership ended signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/7998b41f-114e-8469-c185-e3c7ce116263 returns this record as JSON. POST /v1/companies/enrich returns every signal for sanofi.com.

{
  "signal_id": "7998b41f-114e-8469-c185-e3c7ce116263",
  "signal_type": "news",
  "signal_subtype": "ends_partnership_with",
  "detected_at": "2026-11-03T21:01:00+00:00",
  "company": {
    "name": "Sanofi",
    "domain": "sanofi.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/11/03/3394742/0/en/nurix-therapeutics-announces-sanofi-s-decision-to-discontinue-development-of-stat6-degrader-sar448272.html",
    "title": "Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272",
    "excerpt": "BRISBANE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today announced that Sanofi notified Nurix of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and to terminate the SAR448272 program. As a result of Sanofi’s decision, Nurix does not anticipate receiving any of the future development, regulatory and commercial milestone payments or royalties for which it has been eligible under the collaboration with respect to the SAR448272 program. Nurix remains eligible to receive milestone payments and royalties with respect to its other previously announced licensed programs developed under the collaboration agreement that Sanofi may at its discretion develop further into clinical candidates. Today’s announcement does not change Nurix’s recently issued cash runway guidance, with cash, cash equivalents and marketable securities of $1.1 billion as of August 31, 2026, sufficient to fund operations into the second half of 2029. “While today’s news is disappointing, Nurix remains in a strong position, with a substantial cash runway, three clinical-stage programs across our wholly owned and partnered portfolio, and an exciting preclinical pipeline,” said Arthur T. Sands, M.D., Ph.D., president and...",
    "summary": "Sanofi notified Nurix Therapeutics of its decision to terminate their SAR448272 oral STAT6 degrader development program.",
    "location": "Brisbane, California, United States",
    "planning": false,
    "image_url": "https://ml.globenewswire.com/Resource/Download/65f50366-0a4e-4329-b0f5-f737c6145524",
    "confidence": 0.95,
    "published_at": "2026-11-03T21:01:00Z",
    "location_data": [
      {
        "city": "Brisbane",
        "state": "California",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-11-03",
    "article_sentence": "Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today announced that Sanofi notified Nurix of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and to terminate the SAR448272 program.",
    "related_company_name": "Nurix Therapeutics, Inc.",
    "related_company_domain": "nurixtx.com"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.